{"id":17357,"date":"2013-12-04T03:30:00","date_gmt":"2013-12-04T02:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/bilancio-farmacia-2013-cala-la-spesa-aumentano-le-ricette\/"},"modified":"2013-12-04T03:30:00","modified_gmt":"2013-12-04T02:30:00","slug":"bilancio-farmacia-2013-cala-la-spesa-aumentano-le-ricette","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/bilancio-farmacia-2013-cala-la-spesa-aumentano-le-ricette\/","title":{"rendered":"Pharmacy budget 2013: spending falls, prescriptions increase"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"text-align: left; line-height: 13.5pt; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-outline-level: 3\"><span style=\"font-family: &quot;Helvetica&quot;,&quot;sans-serif&quot;; color: black; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-themecolor: text1; mso-fareast-language: IT\">After six years of legal battle, the Indian Supreme Court has rejected the application of the Swiss pharmaceutical industry for the patent of an anti-cancer drug. The judges ruled that the local industry has the right to produce the drug Glivec as a generic drug to safeguard the population&#039;s right to health<\/p>\n<p><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: 13.5pt; margin: 0cm 0cm 7.5pt; background: white\"><b><span style=\"font-family: &quot;Georgia&quot;,&quot;serif&quot;; color: black; font-size: 9pt; mso-fareast-font-family: 'Times New Roman'; mso-themecolor: text1; mso-fareast-language: IT; mso-bidi-font-family: Helvetica\">Of <a href=\"http:\/\/www.ilfattoquotidiano.it\/blog\/rquotidiano\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: black; text-decoration: none; mso-themecolor: text1; text-underline: none\">Newspaper Il Fatto Quotidiano<\/span><\/a> | <a href=\"http:\/\/www.ilfattoquotidiano.it\/2013\/04\/01\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: black; text-decoration: none; mso-themecolor: text1; text-underline: none\">1<\/span><\/a> <a href=\"http:\/\/www.ilfattoquotidiano.it\/2013\/04\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: black; text-decoration: none; mso-themecolor: text1; text-underline: none\">April 2013<\/span><\/a><\/p>\n<p><\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: 16.5pt; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Helvetica&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">Six years of legal battle between the pharmaceutical giant <b>Novartis<\/b> and the<b>India,<\/b> but already as happened with <b>Roche<\/b> And<b> Bayer<\/b> the supreme judges have put their hand on their conscience by blaming \u201cBig Pharma\u201d. The Indian Supreme Court has rejected the appeal of the Swiss pharmaceutical industry relating to the patent of an anti-cancer drug. According to Cnn Ibn TV, the judges ruled that the local industry has the right to produce the medicine <b>Glivec<\/b> as a generic drug <b>low cost<\/b> to safeguard the <b>Right to health<\/b> of the population. The sentence comes after years of stamped papers and recriminations hired by the Swiss giant to obtain compliance with intellectual property laws. As motivation, the Supreme Court argued that Glivec &quot;is not an innovative product&quot; because it uses an already known molecule and therefore does not fall within the criteria established for &quot;inventions&quot;. Indian human rights defense associations are rejoicing because it is a confirmation of India as the world&#039;s &quot;pharmacy for the poor&quot;.<\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: 16.5pt; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Helvetica&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">Just under a month ago, on March 5, India rejected another appeal; that of the pharmaceutical company Bayer again against a low-cost version of an anti-cancer drug. The German industri had turned to the Intellectual Property Appeals Commission (IPAB) to request the<b>annulment<\/b> of the decision to grant the Indian Natco Pharma a patent to produce the low-cost<b> Nexavar<\/b>used to treat liver cancer<\/p>","protected":false},"excerpt":{"rendered":"<p>Dopo sei anni di battaglia legale la Corte Suprema indiana ha respinto l&#8217;istanza dell&rsquo;industria farmaceutica svizzera per il brevetto di un farmaco anti tumore. I giudici hanno stabilito che l&rsquo;industria locale ha il diritto a produrre il medicinale Glivec come farmaco generico per salvaguardare il diritto alla salute della popolazione di Redazione Il Fatto Quotidiano &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-17357","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=17357"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17357\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=17357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=17357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=17357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}